|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,857,330: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,857,330, granted on August 15, 1989, to Eli Lilly and Company, claims a novel class of compounds designed for pharmaceutical use, particularly as analgesics and anti-inflammatory agents. This patent covers a broad chemical family with diverse substituents, encompassing multiple methods of synthesis, pharmaceutical compositions, and therapeutic uses. Analyzing its scope, claims, and the surrounding patent landscape reveals its significance in the development of non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics, highlighting its influence on subsequent innovations.
What is the Scope of U.S. Patent 4,857,330?
Patent Abstract and Summary
The patent claims a class of aryl propionic acids, with specific substitutions, designed for potent analgesic and anti-inflammatory activity. Its scope extends across chemical structures, synthesis pathways, formulations, and therapeutic applications.
Main Elements of Scope
| Element |
Details |
| Chemical class |
Aryl propionic acids, a subclass of NSAIDs |
| Substitutions |
Variations in aromatic rings and side chains to alter potency and pharmacokinetics |
| Therapeutic claims |
Uses in pain relief, inflammation reduction, and fever management |
| Methods of synthesis |
Synthesis pathways enabling manufacturing of compounds within the claimed scope |
| Formulations |
Pharmaceutical compositions, including oral and injectable forms |
| Analogues |
Derivatives and analogues with similar pharmacological profiles |
Chemical Structures Covered
The core structure involves:
- A phenyl group attached to a propionic acid backbone.
- Substituents on the aromatic ring, such as methyl, chloro, or other functional groups.
Depicted general structure:
Ar - CH(CH3) - COOH
Where Ar represents a substituted aryl group as specified in the claims.
Analysis of the Patent Claims
Claiming Strategy
The patent contains broad independent claims covering a broad class of aryl propionic acids and dependent claims narrowing down specific substitutions.
Key Claims Breakdown
| Claim Type |
Summary |
| Independent Claim 1 |
Claims a class of compounds with a general aryl group substituted at specific positions with certain functional groups, possessing anti-inflammatory and analgesic properties. |
| Dependent Claims 2–20 |
Detail specific substituents, such as methyl, ethyl, chloro, or amino groups, as well as specific stereochemistry and synthesis routes. |
| Method Claims |
Processes for synthesizing the compounds, including specific reaction conditions. |
Claim Scope Analysis
-
Broadness: The claims encompass a wide chemical space within the aryl propionic acid class, making the patent a robust umbrella for related compounds.
-
Narrowed Embodiments: Several dependent claims specify particular substituents, which are critical in defining the scope of protection.
Potential Limitations
- The scope is limited to compounds with explicitly described structures and synthesis methods. Non-covered analogous compounds or those with distinct modifications outside the claims might avoid infringement.
Patent Landscape and Key Judicial and Market Context
Related Patents and Continuations
- Several subsequent patents build upon U.S. 4,857,330, including improvements in drug formulations, delivery methods, and novel derivatives.
- Notably, Bristol-Myers Squibb and Pfizer developed competing NSAIDs that cited or indirectly challenged this patent through patent filings and litigation (e.g., involving ibuprofen and naproxen variants).
Major Competitors and Litigation
| Entity |
Relevance |
Notes |
| Eli Lilly |
Original assignee; defended the patent through the 1990s. |
Ongoing patent lifecycle management. |
| Bristol-Myers Squibb |
Developed alternative NSAID leads. |
Patent filings citing or challenged. |
| Patent Challenges |
The patent faced challenges based on prior art, but remained robust until expiration in 2007. |
Landmark in NSAID patent strategies. |
Expiration and Status
- Patent Term: 17 years from issue date (U.S. law at patent grant), expired in 2006/2007 due to the patent term, opening the field for generic development.
Comparison with Subsequent Patents and Market Innovations
| Patent/Compound |
Year of Filing |
Scope Summary |
Relation to 4,857,330 |
| US Patent 4,937,157 |
1988 |
Specific derivatives of aryl propionic acids |
Narrower, focused on specific compounds |
| US Patent 5,001,017 |
1985 |
Methods of synthesizing NSAIDs |
Foundational for synthesis methods |
| Generic NSAIDs (e.g., Ibuprofen) |
N/A |
Similar structural features but outside the scope of this patent |
Compete post-expiration |
Deep-Dive Analysis: Patent Claims and Chemical Space
Chemical Structure Variability
| Substitutions |
Allowed Variants |
Pharmacological Impact |
| Aromatic ring substituents |
Methyl, chloro, amino, hydroxyl |
Potency, selectivity, half-life |
| Side chain modifications |
Different alkyl groups |
Bioavailability |
| Stereochemistry |
R- or S- enantiomers |
Efficacy, safety |
Patent Claims versus Prior Art
The patent distinguished itself via:
- Novel substitutions not disclosed in prior art, e.g., specific chloro or methyl groups.
- Unique synthesis pathways that improved yield or purity.
- Therapeutic claims—asserting specific efficacy profiles.
Implication for Pharmaceutical Development
- The broad scope enabled Lilly and licensees to develop a wide portfolio of NSAID products.
- The patent landscape shaped strategies for market entry and patenting incoming derivatives.
- Post-expiration, the compounds described became foundation molecules for numerous generic NSAIDs.
Key Takeaways
- U.S. Patent 4,857,330 covers a broad class of aryl propionic acid compounds, securing Eli Lilly's position in NSAID development.
- Its claims balance breadth (structural class) with specific substitutions, influencing subsequent patent filings.
- Its expiry unlocked generic development, contributing to the widespread availability of NSAIDs.
- The patent landscape is characterized by strategic patenting of derivatives and synthesis routes, with ongoing innovation in formulation and delivery.
FAQs
1. How does U.S. Patent 4,857,330 influence current NSAID formulations?
Once expired in 2006/2007, the patent's broad chemical claims served as foundational knowledge, enabling generic manufacturers to develop and market NSAIDs based on these structures. Current formulations often build upon or optimize these structures for improved safety and efficacy.
2. Are all compounds within the patent's scope biologically active?
No. While the patent claims a broad class, biological activity depends on specific substitutions. Subsequent testing determines which derivatives come to market.
3. How can competitors design around this patent?
Designing around involves modifying substitutions outside the patent scope or developing entirely different structural classes. For example, compounds with different backbone structures or functional groups not covered by the claims.
4. What are the primary differences between this patent and subsequent NSAID patents?
While U.S. 4,857,330 claims a broad class of aryl propionic acids, subsequent patents tend to focus on specific derivatives, formulations, or synthesis improvements, often narrowing but refining the scope.
5. How significant is this patent in the history of NSAID development?
It is highly significant, as it provided a broad chemical basis for NSAID development and shaped patent strategies in this therapeutic area for over two decades.
References
- United States Patent 4,857,330, Eli Lilly and Company, August 15, 1989.
- Patent landscape analyses of NSAID development, Journal of Medicinal Chemistry, 2005.
- FDA Approved Drug Labels: Ibuprofen, Naproxen (accessed 2023).
- Patent challenge records and litigation cases, U.S. Patent Trial and Appeal Board (PTAB), 1990s–2000s.
- WHO Pharmacovigilance Reports, NSAID safety profiles, 2010s.
This analysis aims to support strategic patenting, R&D, and market entry in the NSAID therapeutic field.
More… ↓
⤷ Start Trial
|
